Efficacy of oral losartan in recessive dystrophic epidermolysis bullosa.

Downloads
DOI:
https://doi.org/10.26326/2281-9649.35.1.2706How to Cite
Jangid S., Madke B., Saoji V., Singh A.L. 2025. Efficacy of oral losartan in recessive dystrophic epidermolysis bullosa. Eur. J. Pediat. Dermatol. 35 (1):34-7. 10.26326/2281-9649.35.1.2706.
pp. 34-7
Abstract
Dystrophic epidermolysis bullosa is caused by a variation in the COL7A1 gene, which encodes type VII collagen. The severity of the disease depends on the type of genetic variant and the domain of the affected protein. We present the case of a 7-day-old infant with recessive dystrophic epidermolysis bullosa, who was treated with oral losartan and showed significant improvement.
Keywords
epidermolysis bullosa, losartan, newborn